IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs
Information source: Hospices Civils de Lyon
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Indapamide (Drug); Perindopril (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Hospices Civils de Lyon Official(s) and/or principal investigator(s):
Francois GUEYFFIER, MD, Principal Investigator, Affiliation: Hospices Civils de Lyon
Overall contact:
François GUEYFFIER, MD, Phone: 33 472 119 057, Email: francois.gueyffier@chu-lyon.fr
Summary
The principal scientific objective of the trial is to identify the factors that are
associated with differential blood pressure responses between drugs. This may allow
investigators to produce new hypotheses on the pathophysiology of hypertension and on the
mechanisms of drug action.
These factors can be of different types:
- Environmental factors (sodium or alcohol intake);
- Morphological (height, weight, body mass index, body surface area);
- Initial blood pressure;
- Electrocardiogram (ECG) parameters of left ventricular hypertrophy;
- Biological parameters as the activity level of the renin angiotensin aldosterone
system;
- Genetic polymorphisms.
Clinical Details
Official title: IDEAL Study : Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Blood pressure at the end of each 4 week treatment period
Eligibility
Minimum age: 25 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Participants have to be 25 to 60 years of age
- Both genders
- Systolic blood pressure of 140 mmHg or above; diastolic blood pressure of 90 mmHg or
above.
- Cardiovascular risk must not be high, to allow for two periods of 4 weeks of placebo
without ethical concern.
Locations and Contacts
François GUEYFFIER, MD, Phone: 33 472 119 057, Email: francois.gueyffier@chu-lyon.fr
Hôpital Louis Pradel, BRon 69677, France; Recruiting
François GUEYFFIER, MD, Phone: 33 472 119, Ext: 057, Email: francois.gueyffier@chu-lyon.fr
François GUEYFFIER, MD, Principal Investigator
Additional Information
Starting date: October 2004
Last updated: October 3, 2007
|
